Keros Therapeutics Reports $14.2 Million Third-Quarter Net Income
Keros Therapeutics reported third-quarter 2026 revenue of $40.0 million and net income of $14.2 million, versus revenue of $14.3 million and a net loss of $7.3 million a year earlier. The company said its cash and cash equivalents are expected to fund operations into the second half of 2028.
Keros Therapeutics reported third-quarter 2026 revenue of $40.0 million and net income of $14.2 million, compared with revenue of $14.3 million and a net loss of $7.3 million a year earlier. The company said its cash and cash equivalents are expected to fund operations into the second half of 2028…